1097 related articles for article (PubMed ID: 17349996)
1. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
2. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
3. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.
Kumar P; Sunkaraneni S; Sirohi S; Dighe SV; Walker EA; Yoburn BC
Eur J Pharmacol; 2008 Nov; 597(1-3):39-45. PubMed ID: 18789923
[TBL] [Abstract][Full Text] [Related]
4. [(35)S]GTPĪ³S binding and opioid tolerance and efficacy in mouse spinal cord.
Madia PA; Navani DM; Yoburn BC
Pharmacol Biochem Behav; 2012 Mar; 101(1):155-65. PubMed ID: 22108651
[TBL] [Abstract][Full Text] [Related]
5. Continuous opioid agonist treatment dose-dependently regulates mu-opioid receptors and dynamin-2 in mouse spinal cord.
Zhang Q; Purohit V; Yoburn BC
Synapse; 2005 Jun; 56(3):123-8. PubMed ID: 15765525
[TBL] [Abstract][Full Text] [Related]
6. Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo.
Yoburn BC; Gomes BA; Rajashekara V; Patel C; Patel M
Synapse; 2003 Feb; 47(2):109-16. PubMed ID: 12454948
[TBL] [Abstract][Full Text] [Related]
7. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
[TBL] [Abstract][Full Text] [Related]
8. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
[TBL] [Abstract][Full Text] [Related]
9. Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo.
Patel MB; Patel CN; Rajashekara V; Yoburn BC
Mol Pharmacol; 2002 Dec; 62(6):1464-70. PubMed ID: 12435815
[TBL] [Abstract][Full Text] [Related]
10. Clocinnamox antagonism of the antinociceptive effects of mu opioids in squirrel monkeys.
Pitts RC; Allen RM; Walker EA; Dykstra LA
J Pharmacol Exp Ther; 1998 Jun; 285(3):1197-206. PubMed ID: 9618423
[TBL] [Abstract][Full Text] [Related]
11. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
[TBL] [Abstract][Full Text] [Related]
12. In vivo regulation of mu-opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice.
Duttaroy A; Yoburn BC
Synapse; 2000 Aug; 37(2):118-24. PubMed ID: 10881033
[TBL] [Abstract][Full Text] [Related]
13. The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.
Chan K; Brodsky M; Davis T; Franklin S; Inturrisi CE; Yoburn BC
Eur J Pharmacol; 1995 Dec; 287(2):135-43. PubMed ID: 8749027
[TBL] [Abstract][Full Text] [Related]
14. Magnitude of tolerance to fentanyl is independent of mu-opioid receptor density.
Chan KW; Duttory A; Yoburn BC
Eur J Pharmacol; 1997 Jan; 319(2-3):225-8. PubMed ID: 9042594
[TBL] [Abstract][Full Text] [Related]
15. The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation.
Sirohi S; Dighe SV; Walker EA; Yoburn BC
Pharmacol Biochem Behav; 2008 Nov; 91(1):115-20. PubMed ID: 18640146
[TBL] [Abstract][Full Text] [Related]
16. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude.
Allen RM; Dykstra LA
J Pharmacol Exp Ther; 2000 Dec; 295(3):1012-21. PubMed ID: 11082436
[TBL] [Abstract][Full Text] [Related]
18. In vivo homologous regulation of mu-opioid receptor gene expression in the mouse.
Sehba F; Duttaroy A; Shah S; Chen B; Carroll J; Yoburn BC
Eur J Pharmacol; 1997 Nov; 339(1):33-41. PubMed ID: 9450614
[TBL] [Abstract][Full Text] [Related]
19. Opioid receptor regulation in mice.
Yoburn BC; Billings B; Duttaroy A
J Pharmacol Exp Ther; 1993 Apr; 265(1):314-20. PubMed ID: 8386239
[TBL] [Abstract][Full Text] [Related]
20. Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse.
Madia PA; Dighe SV; Sirohi S; Walker EA; Yoburn BC
Psychopharmacology (Berl); 2009 Dec; 207(3):413-22. PubMed ID: 19816677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
